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Undone science and blind spots in medical treatment research
Abstract
Age-related Macular Degeneration (AMD) is a serious eye disease. Two similar drugs, Lucentis and
Avastin, are available to slow the progression of wet AMD. Research has been carried out on the highly
profitable drug Lucentis, so governments have licensed it for use, whereas equivalent research and formal
licensing of Avastin for treatment of eye disease has been delayed and discouraged. This is a case
illustrating the problem of undone science: research in socially beneficial areas may be neglected for
commercial or political reasons.
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ORIGINAL RESEARCH

Undone science and blind spots
in medical treatment research
Tom Cleary
Mr. Silverless and the story of two eye drugs
Mr. Cosmo Silverless was an active 80year-old Australian at the time his central vision
began to fail in July 2005. He not only enjoyed
travelling but was also researching local coal mining
history with a few colleagues. He reports:
This has involved field visits, interviewing
older people, research at Wollongong
Library and the University, reading many
books and writing. It is imperative that I
retain at least partial eyesight to continue
with this work.

He suffers from chronic kidney disease and is on
dialysis and exchange bags four times daily:
This condition has put a stop to major
activities such as flying and travelling long
distances by bus or train. Holidays are
therefore curtailed.

Finally, he has severe arthritis in both knees which
makes walking difficult:
Life would be made far more difficult if I
could no longer drive.

Unfortunately Mr Silverless is one of the
thousands of elderly Australians who live with the
effects of an eye disease called Age-related Macular
Degeneration (AMD). The macular of the eye is
responsible for central vision. This small area of the
retina enables the eye to see detail required for
reading and driving. Mr Silverless is already legally
blind in his right eye due to damage to its macula.
He needs monthly injections into his left eyeball to
keep his left macular area healthy and keep him
from losing his remaining central vision.

Tom Cleary. Optometrist; MA student, University of
Wollongong, NSW, Australia.
Email-e: Htomcleary@live.com.auH
Social Medicine (www.socialmedicine.info)

AMD can leave people over fifty years old with
little or no central vision. It is a major cause of
impaired vision in Australia (AIHW 2005). It can
result in a person being legally blind and unable to
easily perform everyday tasks that require the use of
detailed vision such as reading, writing and even
facial recognition. The central vision loss occurs
slowly with the dry form of AMD or can be lost
suddenly with the wet form of AMD (Guymer
2007). The wet form of AMD has serious
consequences for a large number of people but since
2005 can now be treated with a number of drugs
which target the new blood vessel growth at the
macular.
Avastin
(with
the
generic
name
bevacizumab) and Lucentis (generic name
ranibizumab) are potent forms of a drug that blocks
blood vessel growth factors. They were the product
of an attempt to cure cancer by restricting the blood
supply to growing tumours (Hess 2006). Both of
these drugs were developed by the pharmaceutical
company Genentech.
Avastin eventually received FDA approval
for treatment of some forms of cancer and is quite
expensive at many thousands of dollars per
treatment (Hurwitz and Kabbinavar 2005). But
Avastin was found to also be effective at controlling
wet AMD when given in very small doses allotted
from the larger cancer treatment dose which made it
very cheap (Rosenfeld, et al. 2005).
Lucentis was designed to be exclusively used in
the treatment of wet AMD and underwent extensive
clinical trials in order to demonstrate its safely and
efficacy and was delivered to the market in single
dose form for the treatment of wet AMD
(Steinbrook 2006). Unlike Avastin which was very
cheap, Lucentis was very expensive per treatment
dose. This unprecedented scenario led to increased
costs in some countries such as Australia which
supported and subsidised the use of Lucentis
(O'Shea 2010). In many countries the Avastin-
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versus-Lucentis debate has brought about a
systematic challenge to the status quo of the way
pharmaceuticals are researched and delivered, such
as in the US where research challenging the position
of Lucentis as the standard treatment of wet AMD is
continuing (CATT Research group 2011).
In Australia the case of Mr Silverless highlights
the challenges of meeting best practice clinical
standards and conforming to a complex medical
system. Mr Silverless first lost the central vision of
the right eye in July 2005. When Avastin became
available in Australia in April 2006 Mr Silverless
was given an injection into his right eye and it
reduced the swelling of the retina but the damage
was already too great to have any improvement in
vision and so no further drug treatment was given to
the right eye. As soon as the left eye showed signs
of vision blur and wet AMD blood vessel growth in
June 2007 the eye was treated with an injection of
Avastin and the central vision returned to normal. At
the time the similar drug Lucentis was not used
because it was not yet subsidised by the Australian
government and at $2000 per injection was too
expensive (Avastin was only $100 per injection). Mr
Silverless received a number of monthly injections
of Avastin but then his treatment drug was changed
to Lucentis when it became fully subsidised by the
Australian Government. This treatment of wet AMD
with injections into the eye of both Avastin and
Lucentis is invasive and risky as the treatment is
designed to improve the central vision but, for
example, there is a risk that the vision in the whole
eye can be lost due to potential side effects of the
injection (Wijngaarden and Qureshi 2008).
Despite the risks and the ongoing expense the
ability to maintain Mr Silverless’ central vision is
vital to ensuring his quality of life. Lucentis
treatment is heavily subsidised by the Australian
Government for the treatment of wet AMD. Over
$18,000 per year is required to treat Mr Silverless’
left eye with monthly Lucentis injections. In 2009
over $150 million was spent on Lucentis through the
Australian Government’s Pharmaceutical Benefits
Scheme. This excessive cost has been noted in the
literature:
An ophthalmologist undertaking 30
injections on their morning list would spend
just $535.77 of public money on
pharmaceuticals with Avastin. By contrast,
if they used Lucentis they would spend $59,
460 (O’Shea 2011: 12).
Social Medicine (www.socialmedicine.info)

So although Avastin costs less than one tenth of
the price of Lucentis, the Australian Government’s
own policies and the apparent lack of scientific
testing of Avastin means that it will be some time
before cheaper drug treatments are widely available
through the Australian health system despite the
objections of the treating clinicians (Taylor, et al.
2007).
There is little incentive for the pharmaceutical
and biotechnology companies to conduct this costly
research on the cheaper drug (Mitchell, et al. 2011).
Health systems across the developed world have
faced various barriers to conducting their own
clinical trials on the cheaper drug such as
Genentech’s attempts to restrict the use of Avastin
(Goldstein and Chase 2007). This dilemma, in
which the lack of research on Avastin has held back
the reform of drug treatments for wet AMD, is an
example of what is known as the problem of
undone science. Medical retinal diagnosis and
treatment has become more effective since 2005 but
AMD is such a huge problem for people in the
community that much more needs to be done to be
able to mitigate the impact of this blinding disease.
It has long been recognised that some research
priorities gain precedence over others for political
and economic rather than clinically derived reasons
(Richards 1991). More specifically David Hess
describes science that is left incomplete or underresourced for political and economic reasons as “the
problem of undone science”. According to Hess this
undone science can be the result of a systemic effort
by elites who put structures in place that keep
research from being completed (Hess 2007).
The concept of undone science has emerged
from the sociology of science as a useful tool for
highlighting the politics of research priorities where
alternatives that are less profitable can be readily
marginalized (Frickel, et al. 2009). The undone
science of wet Age-related Macular Degeneration
treatment research can be used to illustrate broader
themes related to the production and direction of
biomedical sciences.
The key to understanding the power of the
undone science of wet AMD treatment is to see the
research that is deliberately left under resourced as a
way of maximising short term profit of
pharmaceutical companies from the patent system.
The drugs Lucentis and Avastin can slow and often
reverse this loss of vision (Mitchell 2011). These

- 235 -

Volume 6, Number 4, December 2011

two drugs are very similar and mainly differ in the
way that the much cheaper drug Avastin has
struggled to attract funding for large scale clinical
trials research (Harvey, et al. 2011). In fact these
drugs were derived from the same humanised mouse
antibody and this was seen as an early threat to
potential profits of Lucentis (Goldstein and Chase
2007). The Avastin research that has been left to one
side is part of a broader group of visual problems
that have been given a lower priority by market
forces guiding much of the research funding
(Wright, et al. 2007).
This paper seeks to investigate how the undone
science of medical retinal drug treatments came to
influence the options available to treat someone like
Mr Silverless, and, more broadly, how the problem
of undone science came to increase the financial and
treatment burden of Age-related Macular
Degeneration on the Australian community.
The role of social theory in the reshaping of
health care
Health professionals take pride in the ongoing
search for best practice. Often evidence based
studies are performed that demand the practitioner
rethink their approach to an area of expertise
(DeMets 2005). Much of the time these studies
come from an area of scientifically recognised
research, but social theory can also influence the
way a health practitioner can think and the way a
health system can function. Each clinical encounter
is an opportunity to apply and adapt best practice
both within the clinic and in the society at large. A
clinical encounter is mediated by communication
occurring in an essentially social space which is one
of the ways the tools provided by social theory can
find immediate application (Leder 1990). Social
reconstruction is a process offered by recent
theorists that in some ways invites a rethinking of
the way technoscientific practices are justified. It is
a process that involves critical analysis of recent
historical cases and has been used in such diverse
areas as the greening of industries, non-weapon
based
defence
and
alternative
medicine
(Woodhouse, et al. 2002). Reconstruction of a social
practice, especially a technoscientific social practice
prone to technocratic absolutism such as evidence
based medicine, is an idea that can be important to
achieving significant reform. Recent political and
economic crises underline that the lack of reform
Social Medicine (www.socialmedicine.info)

and the unsustainable expense of current health
systems represents a fundamental challenge to civil
society.
At certain stages during the period 2005–2010,
the main problem with Avastin use was the lack of
comprehensive clinical trials research, hence
creating a problem of undone science for those who
may have wished to justify its use as a treatment for
wet AMD. As Guymer points out in the March 2007
Medical Journal of Australia (just three months
before Mr Silverless’ left eye was affected by
AMD):
No
prospective
randomised
studies
comparing ranibizumab (Lucentis) and
bevacizumab (Avastin) have taken place,
although there are plans for such a trial
through the US National Eye Institute. Until
the results of such a comparative trial are
forthcoming, government and the community
face a dilemma of whether to approve and
subsidise the well studied but expensive drug
ranibizumab or delay that decision and
therefore condone the off-label use of a drug
(Avastin) that has not been submitted to the
rigours of a randomised clinical trial nor
studies to the extent that we expect before a
new drug is introduced (Guymer 2007: 276).

Despite the recognition that wet AMD is an
extraordinary economic burden to the community
and that it has an enormous impact on quality of life,
many studies simply use economic and
epidemiological data to argue for the relative
benefits of funding research, and subsidising
treatment and diagnosis of wet AMD. This may be
due to ongoing controversy surrounding the
commercialisation of this area of medicine. Studies
that focus on using preventive techniques to reduce
the social impact of AMD and research in low
vision and rehabilitation of visual function in those
people affected by AMD have an important role to
play in addressing this disabling condition (Smith, et
al. 2001).
This case study of Anti-VEGF treatment research
gave an opportunity to apply David Hess’
interpretation of undone science. In Hess’ (2006)
chapter “Antiangiogenesis Research and the
Dynamics of Scientific Fields” he identifies certain
factors as important to the study of undone science:
denaturalization
of
the
material
world,
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universalization of values, expansion of scale and
differentiation of institutions. Hess’ work examines
how certain societal aspects of conducting research
can create a process of uneven development.
Denaturalization of the material world means
that science and technology can tend to become
more distanced from living entities over time. The
idea of denaturalization leads to an understanding of
the importance of identifying patentable substances,
as opposed to substances and preventive techniques
that may be effective but are deemed too natural to
be patented and therefore more difficult to be
converted into a successful drug treatment. In the
case of Lucentis, which was produced specifically
for the treatment of retinal blood vessels, the
question of patent was uncomplicated and the ease
of predicting an economic return meant that research
could be funded.
On the other hand Avastin was already available
as a treatment of bowel cancer when it began to be
used to treat retinal blood vessel growth. This meant
that any research that was conducted on Avastin as a
wet AMD treatment would need to be performed
without the expectation of the same economic
returns as Lucentis. Also, because successful
Avastin research would hurt the profitability of
Lucentis, it is not surprising that the company
conducting Lucentis research would not support the
funding of Avastin research. By denaturalizing the
material world and creating patentable substances
we can see in this case how the priority can quickly
become conducting research in the most
economically productive areas of a scientific field
and allowing the silence of undone science to
marginalize the less profitable alternatives
(Nickisch, et al. 2009).
Hess also describes the universalization of
values, a tendency for fields of science to develop
formal methodologies of dispute resolution such as
the use of Randomised Controlled Trials (RCTs) in
the area of clinical medicine. RCTs are recognized
as the gold standard for evaluating treatment but
also impose large costs and scale requirements on
the required research. This makes the imperative to
use the most economically viable substance more
important when looking to make a profit on
investment in drug treatment options. Phase I, II and
III drug trials can cost many millions of dollars and
are seen as important to ensure that new drug
treatments are safe and effective.
Social Medicine (www.socialmedicine.info)

These experiments are conducted in a way that
attempts to minimise certain forms of bias. But the
social factors at play in undone science are rarely
taken into account when addressing the case for and
against using particular drug treatments. Because
comprehensive research has not been conducted on
Avastin as a treatment for wet AMD, the clinician
who wishes to justify using this drug may point out
that the potential bias of the observer is not the only
relevant bias when evaluating the literature. The
societal factors at play also need to be addressed in
the way they shape the research available to the
clinician.
Expansion of scale is also identified by Hess as
shaping the contours of research, where the cost and
scale of laboratory sciences have expanded faster
than the ability of public institutions to fund
research. As the cost and scale out pace the public
purse, many more organizations seek to bring new
science to the public, some of which are only
involved in order to realize a financial return on
their investment. Thus the way these organizations
go about their business can further shape the
contours of scientific progress. This can be
demonstrated in the case of the privately funded
Lucentis and the public funding of Avastin wet
AMD treatment research. The expansion of scale of
science means that it is not always possible to
conduct research in areas that are for the common
good without a deliberate effort to coordinate public
knowledge resources and work to limit the
exploitative profiteering of engineered ignorance.
So in scientific fields there can be lots of
organizations, both public and private, and large
amounts of money at stake. Hess shows the
importance of the differentiation of these institutions
in shaping science. Hess points out that conflicts
regarding
roles
and
organizational
goals
increasingly arise within and between various fields
of action of science. In the case study of Lucentis
and Avastin this differentiation of institutions has
been identified as a challenge and an opportunity for
bringing about organizational and political change
that can help institutions evolve to serve the
changing needs of the community. For example,
public institutions such as hospitals and professional
organisations can bring about reform of a scientific
field by cooperating in ways that address the lack of
research in an area where there is little hope of a
financial return but huge cost savings for the
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community (O'Shea 2011). Avastin may not be as
profitable a treatment of wet AMD as Lucentis but
there are potential benefits for institutions to
cooperate in order to fund and conduct the relevant
research and work together to incorporate the
findings of this research into the health system
(O’Shea 2011).
Conclusion
Overall an awareness of societal and historical
aspects of technoscientific practices has been shown
in recent literature to be important in the progress of
science and the modernization of society (Kleinman
2005). The incorporation into social studies of
science of cases that demonstrate the extraordinary
effect on the direction of scientific fields exerted by
simply controlling the resources available to
conduct research has been important to
understanding science as a social practice (Proctor
2008). Hess’ study of undone science, when applied
to the treatment of wet AMD, is a robust example of
how societal factors can be the key consideration for
people, both patients and practitioners, in their
everyday encounter with clinical best practice.
An understanding of the implications of
denaturalization of the material in the current era of
patent for profit is important for those seeking
reform. When trying to find ways to resolve
disputes, also essential is finding ways to break
down the problems of institutional differentiation,
expansion of scale and universalization of values.
Civil society should learn to be less tolerant of
convenient blind spots in scientific knowledge that
exist only to advantage those willing to compromise
society’s best interest for short term profit. Thus an
ongoing examination of the way that progress in
biosciences can be interpreted in terms of social
theory such as that of undone science is important
for the global community.
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